Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11681378 | 0.98 | CYP2C19 (0.44) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Hydrochloric Acid SCHEMBL4107889 | 0.98 | CYP2C19 (0.44) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Sulfuric Acid SCHEMBL11682511 | 0.92 | CYP2C19 (0.40) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Phosphoric Acid SCHEMBL11680419 | 0.92 | CYP2C19 (0.40) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL11681060 | 0.91 | CYP2C19 (0.39) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL11677802 | 0.84 | CHEK1 (0.39) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL6330116 | 0.84 | CYP2C19 (0.35) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Water SCHEMBL11678953 | 0.83 | CYP2C19 (0.34) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| Hydrochloric Acid SCHEMBL11679134 | 0.83 | CHEK1 (0.38) | CYP2C19CHEK1DAPK3RETPDGFRB | |
| SCHEMBL7930120 | 0.82 | CHEK1 (0.56) | CYP2C19CHEK1DAPK3RETPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | LEVY ANDREW | 2009-02-26 | — | — | US | claimed |
| WO-2008153908-A1 | USE OF HAPTOGLOBIN GENOTYPING IN DIAGNOSIS AND TREATMENT OF INTRAPLAQUE HEMORRHAGE | RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES (IL) | 2008-12-18 | — | — | WO | claimed |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | SHAPIRO HOWARD K | 2008-09-25 | — | — | US | claimed |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | SECANT PHARMA, LLC | 2005-04-28 | — | — | US | claimed |
| EP-0786994-B1 | USE OF CHLORIDE CHANNEL BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-6444221-B1 | ADMINISTERING AMINOBENZOIC ACID | SECANT PHARMA, LLC | 2002-09-03 | — | — | US | claimed |
| EP-0707446-A4 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 2001-01-10 | — | — | EP | claimed |
| EP-0759750-A4 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1998-05-27 | — | — | EP | claimed |
| US-5705530-A | SIDE EFFECT REDUCTION; GLAUCOMA TREATMENT | ALLERGAN (US) | 1998-01-06 | — | — | US | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| JP-H08512055-A | — | — | 1996-12-17 | — | — | JP | claimed |
| EP-0707446-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO, Howard, K. (US) | 1996-04-24 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995001096-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF FOR TREATMENT OF NEUROLOGICAL DISEASES AND ETIOLOGICALLY RELATED SYMPTOMOLOGY | SHAPIRO HOWARD K (US) | 1995-01-12 | — | — | WO | claimed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | claimed |
| WO-2013119825-A1 | MODULATORS OF TOUSLED KINASE IN CELLULAR PROCESSES | DE BENEDETTI ARRIGO (US) | 2013-08-15 | — | — | WO | disclosed |
| US-8178516-B2 | Composition of 4-guanidinobenzoic acid HCl, a co-agent suitable for systemic administration solely via the oral route, antioxidants, vitamins, metabolites | Sylvan Labs, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| US-4070464-A | DISPIROBENZOXAZINES | MERCK & CO., INC. (US) | 1978-01-24 | — | — | US | disclosed |
| US-4067980-A | Spirobenzoxazinium salts, method of use and compositions thereof as antihypertensive agents | MERCK & CO., INC. (US) | 1978-01-10 | — | — | US | disclosed |
| US-4029816-A | ANTIHYPERTENSIVE, DIURETIC, SALURETIC | MERCK & CO., INC. (US) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054390-A1 | Use of haptoglobin genotyping in diagnosis and treatment of intraplaque hemorrhage resulting from plaque rupture | APOB, PPHLN1, SERPINC1 | CYP2C19 2150/4885CHEK1 4609/4885DAPK3 1557/4885 |
| US-20050090553-A1 | Compositions and method for treatment of chronic inflammatory diseases | PCCA, HMGB1, PTGES | CYP2C19 611/4885CHEK1 2021/4885DAPK3 3957/4885 |
| US-20080234380-A1 | Compositions and method for treatment of chronic inflammatory diseases | HMGB1, PCCA, QSOX1 | CYP2C19 712/4885CHEK1 1948/4885DAPK3 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.